Sign in
TerminatedPhase 3

Improving Neurological Outcome for Acute Basilar Artery Occlusion With Sufficient Recanalization After Thrombectomy by Intraarterial Tenecteplase (INSIST-IT)

Key facts

Who runs it
General Hospital of Shenyang Military Region
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 3
People taking part
145 people enrolled
Started
21 Mar 2023
Ended
18 May 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Tenecteplase
Record updated
2 July 2025
Why it stopped
The interim analysis showed the potential harm of intra-arterial TNK.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age ≥ 18
  • Patients with basilar artery occlusion who received endovascular treatment within 24 hours of estimated time of stroke onset as per BASICS trial definition
  • National Institute of Health Stroke Scale (NIHSS) ≥ 6 before endovascular treatment
  • Successful recanalization (mTICI 2b-3) after endovascular treatment
  • PC-ASPECTS ≥ 6 on CT
  • Absence of parenchymal hematoma on CT images done in the angio suite immediately after the procedure
  • Modified Rankin Scale score before stroke onset ≤ 3
  • Signed informed consent by patient or their legally authorized representative

Who cannot take part

  • Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage
  • After recanalization, severe and sustained (i.e., > 5 minutes) uncontrolled hypertension (systolic blood pressure over 180mmHg or diastolic blood pressure over 105 mmHg) refractory to antihypertensive medication
  • Patients with contraindication or allergic to any ingredient of drugs in our study
  • The estimated life expectancy is less than 6 months due to other serious diseases
  • Other conditions unsuitable for this clinical study assessed by researcher
  • Coagulation disorders, systemic hemorrhagic diathesis, thrombocytopenia (<100000/mm3), or INR > 1.7
  • Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis
  • baseline PC ASPECTS < 5 on CT
  • More than six retrieval attempts in the same vessel
  • Pregnancy, plan to get pregnant or during lactation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The potential benefit of intraarterial tenecteplase in acute basilar artery occlusion (BAO) patients with successful reperfusion following endovascular treatment (EVT) has not been studied. The current study aimed to explore the efficacy and safety of intraarterial tenecteplase in acute BAO patients with successful reperfusion after EVT.

The 2 groups in the trial

  • TNK groupTreatment being tested

    Treatment: Tenecteplase

  • control groupNo study treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Improving Neurological Outcome for Acute Basilar Artery Occlusion With Sufficient Recanalization After Thrombectomy by Intraarterial Tenecteplase (INSIST-IT): a Prospective, Randomized, Open-label, Blinded-end Point, Multicenter Trial
Record updated
2 July 2025